KLP Kapitalforvaltning AS Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP)

KLP Kapitalforvaltning AS purchased a new position in Rapport Therapeutics (NASDAQ:RAPP) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 1,900 shares of the company’s stock, valued at approximately $34,000.

A number of other hedge funds have also recently modified their holdings of the company. Swiss National Bank bought a new stake in shares of Rapport Therapeutics in the fourth quarter worth about $319,000. New York State Common Retirement Fund purchased a new stake in Rapport Therapeutics in the 4th quarter worth approximately $62,000. Jennison Associates LLC purchased a new stake in Rapport Therapeutics in the 4th quarter worth approximately $1,105,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Rapport Therapeutics in the 4th quarter worth approximately $138,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Rapport Therapeutics during the third quarter valued at approximately $83,000.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, CFO Troy A. Ignelzi purchased 9,900 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was bought at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the purchase, the chief financial officer now directly owns 9,900 shares in the company, valued at $99,990. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Wendy B. Young acquired 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were acquired at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Rapport Therapeutics Stock Up 7.3 %

NASDAQ RAPP opened at $9.26 on Friday. The firm has a market capitalization of $337.95 million and a PE ratio of -0.67. The stock’s 50 day moving average is $11.16 and its 200 day moving average is $17.11. Rapport Therapeutics has a twelve month low of $6.43 and a twelve month high of $29.74.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on RAPP shares. JMP Securities began coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They issued a “market outperform” rating and a $28.00 price target on the stock. Citizens Jmp started coverage on shares of Rapport Therapeutics in a research note on Tuesday, April 8th. They set a “mkt outperform” rating on the stock. Four research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $32.67.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.